Navigation Links
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
Date:5/30/2009

ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted in a statistically significant improvement in progression-free survival (PFS), the length of time a patient lives without their cancer growing (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; P<0.001. Median PFS: 14.0 weeks vs. 17.3 weeks, favoring vandetanib). Vandetanib is the first oral targeted therapy to show evidence of clinical benefits when added to chemotherapy in a Phase III study in second line advanced NSCLC(1).

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/astrazeneca/38654/

ZODIAC is a randomized, double-blind, placebo-controlled Phase III study evaluating the combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients previously treated with one prior anti-cancer therapy for advanced NSCLC.

Data from ZEAL(2), a smaller Phase III study also featured on this year's ASCO program, are supportive of ZODIAC although the primary endpoint did not reach statistical significance in the ZEAL study (hazard ratio [HR] 0.86, 97.58% CI 0.69-1.06; P=0.108. Median PFS: 11.9 weeks vs. 17.6 weeks, favouring vandetanib). The combination of vandetanib plus pemetrexed did show a positive trend in prolongation of PFS compared with pemetrexed alone.

ZEAL is a randomized, double-blind, placebo-controlled Phase III study evaluating vandetanib 100mg plus pemetrexed versus pemetrexed alone. The study enrolled 534 patients previously treated with one prior anti-cancer therapy for advance
'/>"/>

SOURCE AstraZeneca Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
2. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
3. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
4. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
5. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
6. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
7. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
8. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
11. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014   ... of advanced cancer genome analysis and testing services, ... discovering and developing highly selective kinase inhibitors for ... genomic study of malignant mixed Mullerian tumors (MMMT), ... reproductive system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/20/2014)... The excitement is building up once again for the annual ... year the Surry Arts Council will be celebrating its 25th year ... are still fans of the Andy Griffith Show. ... CBS from 1960 through 1968. The show ranked by TV ... Mount Airy, North Carolina is where the show was filmed calling ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 2014 Final Cut Pro X Plugin ... of the Information theme for FCPX filmmakers. , “Fun, cool, ... the Information theme,” says Christina Austin, CEO of Pixel Film ... professional.” , Information features easy to use controls that give ... environment. Change the background color, color of each circle outline, ...
(Date:9/20/2014)... 20, 2014 MarijuanaDoctors.com recently returned ... at the PAIN Week conference that was held ... Casino in Las Vegas from September 2nd to ... PAIN Week in the hopes of educating physicians ... and legitimate tool to treat chronic Pain, MarijuanaDoctors.com ...
(Date:9/19/2014)... September 19, 2014 “Copay coupons,” a ... of brand drugs among patients with prescription drug coverage, ... to a new report from the Department of ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... the federal government. , The report highlights that two ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... well-proven medications, could have huge impact, expert says , ... of a statin and a blood pressure-lowering ACE inhibitor ... or stroke reduced their incidence by more than 60 ... the study all had diabetes or a history of ...
... BNVI ) today announced that it has entered into agreements ... price per unit of $6.20 for aggregate gross proceeds of up ... common stock and ten warrants. Each warrant entitles its holder ... price of $0.85. The warrants may be exercised at any ...
... Anterior cruciate ligament (ACL) injuries are one of the ... of patients undergo reconstructive surgery to repair these injuries. ... issue of The Journal of Bone and Joint Surgery ... increasing substantially and women and younger patients are more likely ...
... have demonstrated that a protein called NEDD9 may be required ... to grow. Their findings, based on the study of a ... issue of Cancer Research , available on-line now. ... evidence that directly demonstrates reduced levels of NEDD9 in a ...
... No clear evidence found that Chantix has dangerous side ... News) -- The smoking cessation drug varenicline (Chantix) does ... to a new British study. , In July, the ... carry a "black-box warning" on its packaging, indicating that ...
... iMobile® Care ... ... information to provide essential and practical aid and care during serious situations is crucial and ... able to deliver a timely response, or to administer self-care without a costly physician or ...
Cached Medicine News:Health News:Drug Combo May Prevent Heart Attacks, Strokes 2Health News:Drug Combo May Prevent Heart Attacks, Strokes 3Health News:Bionovo Announces Pricing of Securities Offering 2Health News:Bionovo Announces Pricing of Securities Offering 3Health News:Teenagers and ACL: Tears common and additional surgery likely 2Health News:NEDD9 protein supports growth of aggressive breast cancer 2Health News:Study Counters Warnings on Quit-Smoking Drug 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: